Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Adam Knott, István Láng, Christelle Lévy, Denise A. Yardley, José Bines, Richard D. Gelber, Martine Piccart, José Baselga

New England Journal of Medicine, 2017

German Breast group, Breast International Group, Roche (Switzerland), University of Milan, European Institute of Oncology, University Hospital of Bern, National Institute of Oncology, Centre François Baclesse, Sarah Cannon, Tennessee Oncology, Instituto Nacional do Câncer, Dana-Farber Cancer Institute, Harvard University, Frontier Science & Technology Research Foundation, Frontier Science Foundation, Institut Jules Bordet, Université Libre de Bruxelles, Memorial Sloan Kettering Cancer Center

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1384

Citations

View on Google Scholar

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back